Try our Advanced Search for more refined results
Zappia v. Myovant Sciences Ltd. et al
Case Number:
1:23-cv-08097
Court:
Nature of Suit:
Multi Party Litigation:
Class Action
Judge:
Firms
Companies
Sectors & Industries:
-
January 02, 2024
Myovant, Sumitomo Beat Investor Suit Over Skadden Advice
Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have escaped for good a proposed class action alleging the companies' merger was undervalued because the lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest.
-
November 02, 2023
Myovant, Sumitomo Call Alleged Skadden Conflict Public Info
Executives of Sumitomo Pharma America Inc. and Myovant Sciences Ltd. have urged a New York federal judge to toss a proposed class action claiming the companies' merger was undervalued because lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate the deal had undisclosed conflicts of interest, saying the complaint doesn't show any actual conflicts to begin with.
-
October 11, 2023
2 Firms To Lead Investor Suit Over Myovant-Sumitomo Deal
Two firms have been named lead counsel for a proposed class action against Myovant Sciences Ltd. and Sumitomo Pharma America Inc. claiming lawyers from Skadden Arps Slate Meagher & Flom LLP who helped negotiate a merger between the pharmaceutical companies had undisclosed conflicts that resulted in a low-value deal, causing losses to Myovant minority shareholders.
-
September 14, 2023
Myovant, Sumitomo Deal Hurt By Skadden Conflict, Suit Says
Pharmaceutical companies Myovant Sciences Ltd. and Sumitomo Pharma American Inc. were sued by a shareholder alleging that lawyers from Skadden Arps Slate Meagher & Flom who helped negotiate a merger between the companies had undisclosed conflicts that resulted in lost value to Myovant minority shareholders after the deal went through at what they called a suboptimal price.